Anesthesia and Intensive Care Unit, Department of Biomedical Science and Public Health, Università Politecnica delle Marche, via Tronto 10, 60126 Torrette di Ancona, Italy.
BMC Anesthesiol. 2013 Sep 26;13(1):25. doi: 10.1186/1471-2253-13-25.
The role of recombinant activated protein C (aPC) during sepsis is still controversial. It showed anti-inflammatory effect and improved the microvascular perfusion in experimental models of septic shock. The present study was aimed at testing the hypothesis that recombinant aPC therapy improves the microcirculation during severe sepsis.
Prospective observational study on patients admitted in a 12-beds intensive care unit of a university hospital from July 2010 to December 2011, with severe sepsis and at least two sepsis-induced organ failures occurring within 48 hours from the onset of sepsis, who received an infusion of aPC (24 mcg/kg/h for 96 hours) (aPC group). Patients with contraindications to aPC administration were also monitored (no-aPC group).At baseline (before starting aPC infusion, T0), after 24 hours (T1a), 48 hours (T1b), 72 hours (T1c) and 6 hours after the end of aPC infusion (T2), general clinical and hemodynamic parameters were collected and the sublingual microcirculation was evaluated with sidestream dark-field imaging. Total vessel density (TVD), perfused vessel density (PVD), De Backer score, microvascular flow index (MFIs), the proportion of perfused vessels (PPV) and the flow heterogeneity index (HI) were calculated for small vessels. The perfused boundary region (PBR) was measured as an index of glycocalyx damage. Variables were compared between time points and groups using non parametric or parametric statistical tests, as appropriate.
In the 13 aPC patients mean arterial pressure (MAP), base excess, lactate, PaO2/FiO2 and the Sequential Organ Failure Assessment (SOFA) score significantly improved over time, while CI and ITBVI did not change. MFIs, TVD, PVD, PPV significantly increased over time and the HI decreased (p < 0.05 in all cases), while the PBR did not change. No-aPC patients (n = 9) did not show any change in the microcirculation over time. A positive correlation was found between MFIs and MAP. TVD, PVD and De Backer score negatively correlated with norepinephrine dose, and the SOFA score negatively correlated with MFIs, TVD and PVD.
aPC significantly improves the microcirculation in patients with severe sepsis/septic shock.
NCT01806428.
重组活化蛋白 C(aPC)在脓毒症中的作用仍存在争议。它在感染性休克的实验模型中显示出抗炎作用,并改善了微血管灌注。本研究旨在检验以下假设:即重组 aPC 治疗可改善严重脓毒症期间的微循环。
这是一项 2010 年 7 月至 2011 年 12 月在一所大学医院的 12 张重症监护病房接受治疗的患者的前瞻性观察性研究,这些患者患有严重败血症,且在败血症发作后 48 小时内至少发生了两种败血症引起的器官衰竭,他们接受了 aPC 输注(24 mcg/kg/h 持续 96 小时)(aPC 组)。也对不能接受 aPC 给药的患者进行了监测(无 aPC 组)。在基线(开始 aPC 输注前,T0)、24 小时后(T1a)、48 小时后(T1b)、72 小时后(T1c)和 aPC 输注结束后 6 小时(T2),采集一般临床和血流动力学参数,并使用边流暗场成像评估舌下微循环。计算小血管的总血管密度(TVD)、灌注血管密度(PVD)、德贝克评分、微血管血流指数(MFIs)、灌注血管比例(PPV)和血流异质性指数(HI)。作为糖萼损伤的指标,测量灌注边界区域(PBR)。使用非参数或参数统计检验比较各时间点和组之间的变量,视情况而定。
在 13 名接受 aPC 治疗的患者中,平均动脉压(MAP)、碱剩余、乳酸、PaO2/FiO2 和序贯器官衰竭评估(SOFA)评分随时间显著改善,而 CI 和 ITBVI 没有变化。MFIs、TVD、PVD、PPV 随时间逐渐增加,HI 降低(所有情况下 p<0.05),而 PBR 没有变化。无 aPC 治疗的患者(n=9)在整个研究期间微循环没有任何变化。MFIs 与 MAP 之间存在正相关。TVD、PVD 和德贝克评分与去甲肾上腺素剂量呈负相关,而 SOFA 评分与 MFIs、TVD 和 PVD 呈负相关。
aPC 可显著改善严重脓毒症/感染性休克患者的微循环。
NCT01806428。